Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Recent Advances in Predicting Mortality and Progression of Systemic Sclerosis-Associated Interstitial Lung Disease

  • Park, Moo Suk (Division of Pulmonology, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Younsei University Health System, Yonsei University College of Medicine)
  • Received : 2020.09.05
  • Accepted : 2020.09.09
  • Published : 2020.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014;146:422-36. https://doi.org/10.1378/chest.13-2626
  2. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156:684-91. https://doi.org/10.7326/0003-4819-156-10-201205150-00004
  3. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167:962-9. https://doi.org/10.1164/rccm.2111053
  4. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-66. https://doi.org/10.1164/rccm.201011-1790OC
  5. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014;43:1421-9. https://doi.org/10.1183/09031936.00131813
  6. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2014;145:723-8. https://doi.org/10.1378/chest.13-1474
  7. Lee SH, Park JS, Kim SY, Kim DS, Kim YW, Chung MP, et al. Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Sci Rep 2018;8:4784. https://doi.org/10.1038/s41598-018-23073-3
  8. Lee SH, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, et al. Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study. Respir Res 2016;17:131. https://doi.org/10.1186/s12931-016-0454-0
  9. Lee SH, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, et al. Comparisons of prognosis between surgically and clinically diagnosed idiopathic pulmonary fibrosis using gap model: a Korean national cohort study. Medicine (Baltimore) 2016;95:e3105. https://doi.org/10.1097/md.0000000000003105
  10. Ryerson CJ, O'Connor D, Dunne JV, Schooley F, Hague CJ, Murphy D, et al. Predicting mortality in systemic sclerosisassociated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis. Chest 2015;148:1268-75. https://doi.org/10.1378/chest.15-0003
  11. Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis 2018;77:1326-32. https://doi.org/10.1136/annrheumdis-2018-213201
  12. Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 2020;55:1902026. https://doi.org/10.1183/13993003.02026-2019
  13. Kaenmuang P, Navasakulpong A. Short-term lung function changes and predictors of progressive systemic sclerosisrelated interstitial lung disease. Tuberc Respir Dis 2020 Jul 15 [Epub]. https://doi.org/10.4046/trd.2020.0043.
  14. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, et al. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respir Med 2017;127:51-6. https://doi.org/10.1016/j.rmed.2017.04.012
  15. Nurmi HM, Purokivi MK, Karkkainen MS, Kettunen HP, Selander TA, Kaarteenaho RL. Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease? BMC Pulm Med 2017;17:16. https://doi.org/10.1186/s12890-016-0358-2
  16. Kim HC, Lee JS, Lee EY, Ha YJ, Chae EJ, Han M, et al. Risk prediction model in rheumatoid arthritis-associated interstitial lung disease. Respirology 2020 May 22 [Epub]. https://doi.org/10.1111/resp/13848.
  17. Brusca RM, Pinal-Fernandez I, Psoter K, Paik JJ, Albayda J, Mecoli C, et al. The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. Respir Med 2019;150:63-5. https://doi.org/10.1016/j.rmed.2019.02.015
  18. Kobayashi H, Naito T, Omae K, Omori S, Nakashima K, Wakuda K, et al. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease. Lung Cancer 2018;121:48-53. https://doi.org/10.1016/j.lungcan.2018.04.023
  19. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54. https://doi.org/10.1164/rccm.200706-877OC
  20. Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis 2019;78:122-30. https://doi.org/10.1136/annrheumdis-2018-213708
  21. Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017;69:1670-8. https://doi.org/10.1002/art.40130
  22. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019;380:2518-28. https://doi.org/10.1056/NEJMoa1903076
  23. Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res 2019;20:13. https://doi.org/10.1186/s12931-019-0980-7

Cited by

  1. Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions vol.5, pp.1, 2021, https://doi.org/10.23838/pfm.2020.00205